FGFR2 and breast carcinoma: However, we found no evidence for loci with stronger effects than FGFR2. Although we observed an association with a novel locus at ZNF365 that appears also to be a risk factor for sporadic breast cancer, overall, our results suggest that there are no common variants with major effects (i.e., OR>2.0) that are specific in BRCA2 carriers.